VRTX

Vertex Pharmaceuticals
D

VRTX

397.15
USD
0.58
(0.15%)
مغلق
حجم التداول
432,538
الربح لكل سهم
0
العائد الربحي
-
P/E
-207
حجم السوق
102,277,757,524
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ 3 أشهر
    buy
    2024-08-22 10:31
    VRTX Chart
    المزيد
أصول ذات صلة
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BIIB
    BIIB
    -0.780
    (-0.53%)
    146.590 USD
    B
    BMRN
    0.695
    (1.07%)
    65.680 USD
    E
    EXEL
    -0.390
    (-1.16%)
    33.280 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    I
    IONS
    0.040
    (0.11%)
    35.630 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    المزيد
الأخبار

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.